These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20100793)

  • 1. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting.
    Hallinen TA; Soini EJ; Eklund K; Puolakka K
    Rheumatology (Oxford); 2010 Apr; 49(4):767-77. PubMed ID: 20100793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ; Hallinen TA; Puolakka K; Vihervaara V; Kauppi MJ
    J Med Econ; 2012; 15(2):340-51. PubMed ID: 22168785
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china.
    Wu B; Wilson A; Wang FF; Wang SL; Wallace DJ; Weisman MH; Lu LJ
    PLoS One; 2012; 7(10):e47373. PubMed ID: 23056637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
    Kvamme MK; Lie E; Uhlig T; Moger TA; Kvien TK; Kristiansen IS
    Rheumatology (Oxford); 2015 Jul; 54(7):1226-35. PubMed ID: 25573840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
    Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis.
    Spalding JR; Hay J
    Pharmacoeconomics; 2006; 24(12):1221-32. PubMed ID: 17129076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Bermejo I; Ren S; Simpson E; Clowes M; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Dec; 36(12):1427-1437. PubMed ID: 29882210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.
    Bansback NJ; Brennan A; Ghatnekar O
    Ann Rheum Dis; 2005 Jul; 64(7):995-1002. PubMed ID: 15550533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis.
    Huoponen S; Aaltonen KJ; Viikinkoski J; Rutanen J; Relas H; Taimen K; Puolakka K; Nordström D; Blom M
    PLoS One; 2019; 14(7):e0220142. PubMed ID: 31339961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV; Chiou CF; Dubois RW
    J Manag Care Pharm; 2006 Sep; 12(7):555-69. PubMed ID: 16981801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of TNF-alpha-blocking agents in the treatment of rheumatoid arthritis.
    Merkesdal S; Ruof J; Mittendorf T; Zeidler H
    Expert Opin Pharmacother; 2004 Sep; 5(9):1881-6. PubMed ID: 15330726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden.
    Kobelt G; Eberhardt K; Geborek P
    Ann Rheum Dis; 2004 Jan; 63(1):4-10. PubMed ID: 14672883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis.
    Lopatina E; Marshall DA; Coupal L; Le Lorier J; Choquette D
    Curr Med Res Opin; 2021 Jan; 37(1):157-166. PubMed ID: 33136462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP; Incerti D; Mutebi A; Peneva D; MacEwan JP; Stolshek B; Kaur P; Gharaibeh M; Strand V
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice.
    Virkki LM; Konttinen YT; Peltomaa R; Suontama K; Saario R; Immonen K; Jäntti J; Tuomiranta T; Nykänen P; Hämeenkorpi R; Heikkilä S; Isomäki P; Nordström D
    Clin Exp Rheumatol; 2008; 26(6):1059-66. PubMed ID: 19210870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.